10 Analysts Have This to Say About Coherus BioSciences
Portfolio Pulse from Benzinga Insights
In the last quarter, Coherus BioSciences (NASDAQ:CHRS) received 9 bullish and 1 somewhat bullish ratings from analysts. The company's average 12-month price target is $21.6, an increase of 1.65% from the previous average of $21.25.
July 14, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences received mostly bullish ratings from analysts, with an increased 12-month price target, indicating a positive outlook for the company.
The majority of analysts gave Coherus BioSciences a bullish rating, indicating a positive sentiment towards the company's stock. Additionally, the increase in the average 12-month price target suggests that analysts expect the company's stock price to rise in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100